haloperidol has been researched along with Amphetamine Abuse in 14 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The Zelen II design method was used; 124 patients with acute mental disorders due to amphetamine were randomly divided into olanzapine group (n = 63) and haloperidol group (n = 61)." | 9.27 | Olanzapine and haloperidol for the treatment of acute symptoms of mental disorders induced by amphetamine-type stimulants: A randomized controlled trial. ( Chen, X; Fan, Q; Song, Y; Tang, J; Xue, X; Yu, X, 2018) |
| "The Zelen II design method was used; 124 patients with acute mental disorders due to amphetamine were randomly divided into olanzapine group (n = 63) and haloperidol group (n = 61)." | 5.27 | Olanzapine and haloperidol for the treatment of acute symptoms of mental disorders induced by amphetamine-type stimulants: A randomized controlled trial. ( Chen, X; Fan, Q; Song, Y; Tang, J; Xue, X; Yu, X, 2018) |
| "Methamphetamine abuse remains an alarming public heath challenge, with no approved pharmacotherapies available." | 3.83 | Agmatine attenuates the discriminative stimulus and hyperthermic effects of methamphetamine in male rats. ( Li, J; Li, JX; Qiu, Y; Thorn, DA, 2016) |
| "This report attempts to highlight that use of an antipsychotic and concurrent chronic use of methamphetamine can cause drug-induced parkinsonism." | 1.42 | Drug-induced parkinsonism following chronic methamphetamine use by a patient on haloperidol decanoate. ( Gedzior, JS; Matthew, BJ, 2015) |
| " We compared the effects of withdrawal from long-term administration of the typical neuroleptic haloperidol (Hal) and/or the atypical agent risperidone (Ris) on MDS and NDS, behaviorally evaluated by amphetamine-induced locomotor stimulation (AILS) and apomorphine-induced stereotypy (AIS) in mice, respectively." | 1.35 | Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors. ( Callegaro-Filho, D; Carvalho, RC; Frussa-Filho, R; Fukushiro, DF; Helfer, DC; Sanday, L; Silva, RH; Trombin, TF; Zanlorenci, LH, 2009) |
| " The AMPH-suppressed SIP manifested again following 5-days of pretreatment with a sub-threshold dosage of AMPH (1." | 1.35 | Role of dopaminergic DAD1 and DAD2 receptors in the sensitization of amphetamine-suppressed schedule-induced polydipsia in rats. ( Lin, PJ; Liu, YP; Tseng, CJ; Tung, CS; Wan, FJ, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (78.57) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xue, X | 1 |
| Song, Y | 1 |
| Yu, X | 1 |
| Fan, Q | 1 |
| Tang, J | 1 |
| Chen, X | 1 |
| Matthew, BJ | 1 |
| Gedzior, JS | 1 |
| Thorn, DA | 1 |
| Li, J | 1 |
| Qiu, Y | 1 |
| Li, JX | 1 |
| Shoptaw, SJ | 2 |
| Kao, U | 2 |
| Ling, WW | 1 |
| Ling, W | 1 |
| Carvalho, RC | 1 |
| Fukushiro, DF | 1 |
| Helfer, DC | 1 |
| Callegaro-Filho, D | 1 |
| Trombin, TF | 1 |
| Zanlorenci, LH | 1 |
| Sanday, L | 1 |
| Silva, RH | 1 |
| Frussa-Filho, R | 1 |
| Kubakawa, T | 1 |
| Niimura, H | 1 |
| Liu, YP | 1 |
| Lin, PJ | 1 |
| Tseng, CJ | 1 |
| Wan, FJ | 1 |
| Tung, CS | 1 |
| Hsieh, HC | 1 |
| Li, HY | 1 |
| Lin, MY | 1 |
| Chiou, YF | 1 |
| Lin, SY | 1 |
| Wong, CH | 1 |
| Chen, JC | 1 |
| Sacchetti, E | 1 |
| Valsecchi, P | 1 |
| Ozaki, S | 1 |
| Leelahanaj, T | 1 |
| Kongsakon, R | 1 |
| Netrakom, P | 1 |
| Kusayama, T | 1 |
| Watanabe, S | 1 |
| Cancela, LM | 1 |
| Basso, AM | 1 |
| Martijena, ID | 1 |
| Capriles, NR | 1 |
| Molina, VA | 1 |
4 reviews available for haloperidol and Amphetamine Abuse
| Article | Year |
|---|---|
Treatment for amphetamine psychosis.
Topics: Amphetamine-Related Disorders; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Olanzapin | 2008 |
Treatment for amphetamine psychosis.
Topics: Amphetamine-Related Disorders; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Olanzapin | 2009 |
[Psychiatric care for patients with addiction of amphetamine, CNS stimulant].
Topics: Adult; Amphetamine; Amphetamine-Related Disorders; Antipsychotic Agents; Crime; Female; Haloperidol; | 2009 |
[Methylphenidate-induced psychiatric disorders].
Topics: Adult; Amphetamine-Related Disorders; Antipsychotic Agents; Central Nervous System Stimulants; Drug | 2003 |
2 trials available for haloperidol and Amphetamine Abuse
| Article | Year |
|---|---|
Olanzapine and haloperidol for the treatment of acute symptoms of mental disorders induced by amphetamine-type stimulants: A randomized controlled trial.
Topics: Adult; Amphetamine; Amphetamine-Related Disorders; Antipsychotic Agents; Benzodiazepines; Brief Psyc | 2018 |
A 4-week, double-blind comparison of olanzapine with haloperidol in the treatment of amphetamine psychosis.
Topics: Adult; Amphetamine-Related Disorders; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Fe | 2005 |
8 other studies available for haloperidol and Amphetamine Abuse
| Article | Year |
|---|---|
Drug-induced parkinsonism following chronic methamphetamine use by a patient on haloperidol decanoate.
Topics: Adult; Amphetamine-Related Disorders; Diphenhydramine; Dose-Response Relationship, Drug; Drug Intera | 2015 |
Agmatine attenuates the discriminative stimulus and hyperthermic effects of methamphetamine in male rats.
Topics: Agmatine; Amphetamine-Related Disorders; Animals; Discrimination Learning; Dopamine Antagonists; Dos | 2016 |
Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors.
Topics: Amphetamine-Related Disorders; Animals; Antipsychotic Agents; Apomorphine; Corpus Striatum; Dopamine | 2009 |
Role of dopaminergic DAD1 and DAD2 receptors in the sensitization of amphetamine-suppressed schedule-induced polydipsia in rats.
Topics: Amphetamine; Amphetamine-Related Disorders; Animals; Behavior, Animal; Benzazepines; Dopamine Agents | 2009 |
Spatial and temporal profile of haloperidol-induced immediate-early gene expression and phosphoCREB binding in the dorsal and ventral striatum of amphetamine-sensitized rats.
Topics: Amphetamine; Amphetamine-Related Disorders; Animals; Basal Ganglia; Cyclic AMP Response Element-Bind | 2002 |
Quetiapine, clozapine, and olanzapine in the treatment of tardive dyskinesia induced by first-generation antipsychotics: a 124-week case report.
Topics: Amphetamine-Related Disorders; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; | 2003 |
Reinforcing effects of methamphetamine in planarians.
Topics: Amphetamine-Related Disorders; Animals; Behavior, Animal; Benzazepines; Brain; Conditioning, Psychol | 2000 |
A dopaminergic mechanism is involved in the 'anxiogenic-like' response induced by chronic amphetamine treatment: a behavioral and neurochemical study.
Topics: Amphetamine; Amphetamine-Related Disorders; Animals; Anxiety; Behavior, Animal; Benzazepines; Brain; | 2001 |